1
|
Kotani K, Iwata A, Kukimoto I, Nishio E, Mitani T, Tsukamoto T, Ichikawa R, Nomura H, Fujii T. Nomogram for predicted probability of cervical cancer and its precursor lesions using miRNA in cervical mucus, HPV genotype and age. Sci Rep 2022; 12:16231. [PMID: 36171233 PMCID: PMC9519568 DOI: 10.1038/s41598-022-19722-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 09/02/2022] [Indexed: 11/17/2022] Open
Abstract
Cervical cancer is the fourth most common cancer in women worldwide. Although cytology or HPV testing is available for screening, these techniques have their drawbacks and optimal screening methods are still being developed. Here, we sought to determine whether aberrant expression of miRNAs in cervical mucus could be an ancillary test for cervical neoplasms. The presence of miRNAs in 583 and 126 patients (validation and external cohorts) was determined by real-time RT-PCR. Performance of a combination with five miRNAs (miR-126-3p, -451a -144-3p, -20b-5p and -155-5p) was estimated by ROC curve analysis. Predicted probability (PP) was estimated by nomograms comprising -ΔCt values of the miRNAs, HPV genotype and age. A combination of five miRNAs showed a maximum AUC of 0.956 (95% CI: 0.933–0.980) for discriminating cancer. Low PP scores were associated with good prognosis over the 2-year observation period (p < 0.05). Accuracy for identifying cancer and cervical intraepithelial neoplasia (CIN) 3 + by nomogram was 0.983 and 0.966, respectively. PP was constant with different storage conditions of materials. We conclude that nomograms using miRNAs in mucus, HPV genotype and age could be useful as ancillary screening tests for cervical neoplasia.
Collapse
Affiliation(s)
- Kiriko Kotani
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Aya Iwata
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Iwao Kukimoto
- Pathogen Genomics Center, National Institute of Infectious Diseases, 4-7-1, Gakuen, Tokyo, Musashi-murayama, 208-0011, Japan
| | - Eiji Nishio
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Takeji Mitani
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Tetsuya Tsukamoto
- Department of Pathology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Ryoko Ichikawa
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Hiroyuki Nomura
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan
| | - Takuma Fujii
- Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, 1-98Dengakugakubo, Toyoake, Aichi, 470-1192, Japan.
| |
Collapse
|
2
|
Induction of Apoptosis and Regulation of MicroRNA Expression by (2 E,6 E)-2,6- bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) Treatment on MCF-7 Breast Cancer Cells. Molecules 2021; 26:molecules26051277. [PMID: 33652854 PMCID: PMC7956517 DOI: 10.3390/molecules26051277] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 02/22/2021] [Accepted: 02/23/2021] [Indexed: 01/19/2023] Open
Abstract
(2E,6E)-2,6-bis-(4-hydroxy-3-methoxybenzylidene)-cyclohexanone (BHMC) is a synthetic curcumin analogue, which has been reported to possess anti-tumor, anti-metastatic, and anti-invasion properties on estrogen receptor (ER) negative breast cancer cells in vitro and in vivo. However, the cytotoxic effects of BHMC on ER positive breast cancer cells were not widely reported. This study was aimed to investigate the cytotoxic potential of BHMC on MCF-7 cells using cell viability, cell cycle, and apoptotic assays. Besides, microarray and quantitative polymerase chain reaction (qPCR) were performed to identify the list of miRNAs and genes, which could be dysregulated following BHMC treatment. The current study discovered that BHMC exhibits selective cytotoxic effects on ER positive MCF-7 cells as compared to ER negative MDA-MB-231 cells and normal breast cells, MCF-10A. BHMC was shown to promote G2/M cell cycle arrest and apoptosis in MCF-7 cells. Microarray and qPCR analysis demonstrated that BHMC treatment would upregulate several miRNAs like miR-3195 and miR-30a-3p and downregulate miRNAs such as miR-6813-5p and miR-6132 in MCF-7 cells. Besides, BHMC administration was also found to downregulate few tumor-promoting genes like VEGF and SNAIL in MCF-7. In conclusion, BHMC induced apoptosis in the MCF-7 cells by altering the expressions of apoptotic-regulating miRNAs and associated genes.
Collapse
|
3
|
Borisov E, Knyazeva M, Novak V, Zabegina L, Prisyazhnaya T, Karizkiy A, Berlev I, Malek A. Analysis of Reciprocally Dysregulated miRNAs in Eutopic Endometrium Is a Promising Approach for Low Invasive Diagnostics of Adenomyosis. Diagnostics (Basel) 2020; 10:E782. [PMID: 33022981 PMCID: PMC7601074 DOI: 10.3390/diagnostics10100782] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 09/26/2020] [Accepted: 10/01/2020] [Indexed: 01/07/2023] Open
Abstract
Endometriosis is a chronic disease characterized by the growth of endometrial tissue outside of the uterine cavity. Endometriosis affects up to 10% of women of reproductive age and has great social impact. The diagnostics of endometriosis are based on clinical appearance, ultrasound, and magnetic resonance imaging (MRI); however, a diagnosis is frequently hampered by the absence of objective criteria. Adenomyosis (AM) is a particular type of endometriosis wherein the spread of the ectopic endometrial gland is limited by the uterine myometrium. Alteration of the microRNA expression profile in the eutopic endometrium can be associated with AM, and may be assayed for diagnostic purposes. In the presented study, we aimed to explore the diagnostic potency of this approach. Eutopic endometrium specimens were collected from patients (n = 33) and healthy women (n = 30). The microRNA expression was profiled to select individual microRNAs with AM-associated expression alterations. A new method of two-tailed RT-qPCR microRNA analysis was applied to assay potential markers. The expression ratios of reciprocally dysregulated microRNAs were calculated, and the diagnostic potency of these parameters was evaluated by receiver operation curve (ROC) analysis. Mir-10b, miR-200c and miR-191 were significantly dysregulated in the eutopic endometrium of AM patients. The expression ratio of reciprocally dysregulated microRNAs allowed us to diagnose AM with a range of sensitivity from 65% to 74%, and of specificity from 72% to 86%. The analysis of microRNAs from the eutopic endometrium might present a promising low-invasive method of AM diagnostics.
Collapse
Affiliation(s)
- Evgeny Borisov
- Subcellular Technology Lab., N.N. Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia; (E.B.); (M.K.); (L.Z.); (I.B.)
- Oncosystem Ltd., 121205 Moscow, Russia
| | - Margarita Knyazeva
- Subcellular Technology Lab., N.N. Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia; (E.B.); (M.K.); (L.Z.); (I.B.)
- Oncosystem Ltd., 121205 Moscow, Russia
- Institute of Biomedical Systems and Biotechnologies, Peter the Great St. Petersburg Polytechnic University, 195251 Saint-Petersburg, Russia
| | - Veronika Novak
- Department of Obstetrics and Gynecology, North-Western State Medical University Named after I.I. Mechnikov, 195067 Saint-Petersburg, Russia; (V.N.); (T.P.)
| | - Lidia Zabegina
- Subcellular Technology Lab., N.N. Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia; (E.B.); (M.K.); (L.Z.); (I.B.)
- Oncosystem Ltd., 121205 Moscow, Russia
- Institute of Biomedical Systems and Biotechnologies, Peter the Great St. Petersburg Polytechnic University, 195251 Saint-Petersburg, Russia
| | - Tatyana Prisyazhnaya
- Department of Obstetrics and Gynecology, North-Western State Medical University Named after I.I. Mechnikov, 195067 Saint-Petersburg, Russia; (V.N.); (T.P.)
| | - Aleksey Karizkiy
- Information Technologies and Programming Faculty, Information Technologies, Mechanics and Optics University, 197101 Saint-Petersburg, Russia;
| | - Igor Berlev
- Subcellular Technology Lab., N.N. Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia; (E.B.); (M.K.); (L.Z.); (I.B.)
- Department of Obstetrics and Gynecology, North-Western State Medical University Named after I.I. Mechnikov, 195067 Saint-Petersburg, Russia; (V.N.); (T.P.)
| | - Anastasia Malek
- Subcellular Technology Lab., N.N. Petrov National Medical Research Center of Oncology, 197758 Saint-Petersburg, Russia; (E.B.); (M.K.); (L.Z.); (I.B.)
- Oncosystem Ltd., 121205 Moscow, Russia
| |
Collapse
|